Business Context and Reporting Period
This Form 8-K filing by Organogenesis Holdings Inc. (ORGO) reports a corporate governance event dated March 10, 2020. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific executive severance package:
- Severance Salary Continuation: $206,000 (payable over 6 months).
- Settlement Payment: $42,400 (related to a prior settlement with Kenneth L. Horton).
- Transition Services: $15,450 per month for 6 months.
- Benefits: Continuation of certain benefit coverage for 6 months and executive outplacement services for up to 1 year.
Material Changes
The primary material change is the departure of Howard Walthall, who resigned as Executive Vice President, Strategy and Market Development, effective immediately on March 10, 2020. A Separation Agreement was executed on March 13, 2020.
Management Commentary and Risks
The filing notes that the Separation Agreement includes a general release by Mr. Walthall of any claims against the Company. No forward-looking guidance, outlook, or discussion of broader business risks is included in this specific report.
Investor Verification Checklist
- Verify the total cash outflow impact of the severance package ($206,000 + $42,400 + $92,700 in transition fees).
- Confirm the strategic implications of the departure of the Executive Vice President of Strategy and Market Development.
- Review the full text of the Separation Agreement (Exhibit 10.1) for any non-compete or confidentiality clauses not summarized here.